New treatments for psoriasis: Which biologic is best?

Journal of Dermatological Treatment

Volumn 17, Issue 2, 2006, Pages 96-107

  Nelson, Andrew A ^a   Pearce, Daniel J ^a   Fleischer Jr , Alan B ^a   Balkrishnan, Rajesh ^b   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Biologies; Cost effectiveness; DLQI; Efficacy; PASI 75; Quality of life; Safety profiles

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ABDOMINAL PAIN; APLASTIC ANEMIA; ARTHRITIS; ARTICLE; CHILL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; DEMYELINATING DISEASE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MYALGIA; NAUSEA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PATIENT EDUCATION; PHARYNGITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; RASH; THROMBOCYTOPENIA; TREATMENT PLANNING; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; INJECTIONS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; UNITED STATES;

EID: 33646545350     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600552273     Document Type: Article

References (42)

1. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430-4.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1): 401-7.
3. Krueger G, Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53(1 suppl 1): S94-100.
4. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49(2 suppl): S44-50.
5. Berridge MJ. Lymphocyte activation in health and disease. Crit Rev Immunol. 1997;17:155-78.
6. Schonherr E, Beavan LA, Hausser H, Kresse H, Culp LA. Differences in decorin expression by papillary and reticular fibroblasts in vivo and in vitro. Biochem J. 1993;290:893-9.
7. Asadullah K, Docke WD, Volk HD, Sterry W. The pathophysiological role of cytokines in psoriasis. Drugs Today (Barc). 1999;35:913-24.
8. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994;24:2377-82.
9. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4:1525-33.
10. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61(2 suppl): 11-21.
11. Biogen Idec Inc, Amevive (alefacept) package insert; 2005. Cambridge, MA, USA.
12. Genentech Inc, Raptiva (efalizumab) package insert; 2005. South San Fransisco, CA, USA.
13. Immunex Corporation, Enbrel (etanercept) package insert; 2005. Thousand Oaks, CA, USA.
14. Centocor Inc, Remicade (infliximab) package insert; 2005. Malvern, PA, USA.
15. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-42.
16. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-7.
17. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-74.
18. Abbott Laboratories, Humira (adalimumab) package insert; 2005. Abbott Park, IL, USA.
19. Chen DM, Gordon KB, Leonardi CL, Menter MA. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. J Am Acad Dermatol. 2004;50(suppl)(3): 1.
20. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with, psoriasis. N Engl J Med. 2003;349:2014-22.
21. Gottlieb AB, Matheson RT, Lowe N, Krueger G, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32.
22. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al., Etanercept Psoriasis Study Group, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12.
23. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al., Efalizumab Study Group, Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 Pt 1): 425-33.
24. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-8.
25. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13.
26. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-80.
27. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-27.
28. Ortonne J. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2): 12-16.
29. Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol. 2001;137:352-3.
30. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236-44.
31. Leary MR, Rapp SR, Herbst KC, Exum ML, Feldman SR. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol. 1998;17:530-6.
32. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-16.
33. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
34. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149:318-22.
35. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in dermatology life quality index scores. Br J Dermatol. 2002;147(suppl 62): 50.
36. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-9.
37. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954-60.
38. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 2003;206:307-15.
39. 2004 Drug topics red book: pharmacy's fundamental reference. Montvale, NJ: Blackwell, 2004.
40. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al., British Association of Dermatologists, British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153:486-97.
41. TNF neutralization in MS: results of a randomized., placebo-controlled multicenter study. 1999: The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999;53:457-65.
42. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-9.